

Technology Advisory Committee D Interests Register

**Topic: Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease
[ID6222]**

Publication Date: TBC

| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Comments |
|-----------------------|------------------|-------------------------------------|--|---|--|
| Will Sullivan | Committee Member | Direct - Financial | <p>Will is part of a team providing ongoing health economic consultancy services to Eisai Canada concerning the technology lemborexant to treat insomnia.</p> <p>Will is part of a team providing ongoing health economic consultancy services to Novartis concerning the technology asciminib to treat newly diagnosed chronic myelogenous leukaemia.</p> | <p>06/06/2024</p> <p>15/01/2025</p> <p>14/05/2025</p> | It was agreed that Will's declaration would not prevent him from participating in discussions on this appraisal. |
| Professor David Meads | Committee Member | Direct – non-financial professional | Professor Meads' employer, the University of Leeds, has received funding from Takeda for research in an unrelated area. | <p>13/06/2024</p> <p>15/01/2025</p> <p>14/05/2025</p> | It was agreed that Professor Meads' declaration would not prevent him from participating in discussions on this appraisal. |

| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Comments |
|--------------------|--|-----------------------|---|--|--|
| Dr Matthew Bradley | Committee Member | Direct - Financial | Dr Bradley's company is co-developing latozinemab (AL001), an investigational human monoclonal antibody designed to modulate progranulin (PGRN), a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, including frontotemporal dementia (FTD), Alzheimer's disease, and Parkinson's disease. Latozinemab is currently in Ph3 development for frontotemporal dementia with a progranulin gene mutation (FTD-GRN). | 10/06/2024 14/05/2025 | It was agreed that Dr Bradley's declaration would prevent him from participating in discussions on this appraisal. |
| Dr Jacoline Bouvy | NICE Programme Director - Medicines Evaluation | Direct – Professional | Dr Bouvy is co-author of the Landeiro et al 2020 paper which is referenced in the company submission. | 03/07/2024 15/01/2025 14/05/2025 | It was agreed that Dr Bouvy's declaration would not prevent her from participating in discussions on this appraisal. |
| Professor Nick Fox | Clinical Expert | Direct - Professional | Professor Fox has served on advisory boards, provided consultancy services, or spoken at meetings for several pharmaceutical companies including Eisai, Eli Lilly, Biogen, Ionis and Roche for which | 11/12/2024 15/01/2025 14/05/2025 | It was agreed that Professor Fox's declaration would not prevent him from providing |

| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Comments |
|----------------|-----------------|-----------------------|---|---|--|
| | | | <p>his employer, UCL, received payments. The focus was on clinical trials in Alzheimer's disease.</p> <p>Professor Fox is a member and former Chair of the Alzheimer's Society Research Strategy Council, which is his nominating organisation.</p> | | expert advice to the committee. |
| Dr Tomas Welsh | Clinical Expert | Direct - Professional | <p>Dr Welsh is the site PI for the TRAILBLAZER-5 study (donanemab).</p> <p>Dr Welsh is Research and Medical Director of The Research Institute for the Care of Older People (RICE), Bath, UK, which runs a mixture of commercial and non-commercial research activity. Commercial research projects run in the Institute have been funded by: Lilly, Roche, Biogen, Eisai, Janssen, AC Immune, Novo Nordisk, Pfizer, Elan, Immunobrain, Actinogen, and Julius Clinical. RICE is a member of the</p> | <p>03/07/2024</p> <p>29/01/2024</p> <p>15/01/2025</p> <p>14/05/2025</p> | It was agreed that Dr Welsh's declaration would not prevent him from providing expert advice to the committee. |

| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Comments |
|------------------|----------------------|------------------------|--|--|--|
| | | | European Alzheimer's Disease Consortium (EADC) | | |
| Peter Almond | Patient Expert | Direct - Personal | Peter has been a participant in a donanemab trial since 2021. | 17/01/2024 | It was agreed that Peter's declaration would not prevent him from providing expert advice to the committee. |
| Dr Jeremy Isaacs | Commissioning Expert | Direct - financial | Dr Isaacs has received conference expenses and consultancy fees (paid to his institution) from Roche, a speaker's fee (paid to his institution) from Biogen and payment from Nestle Health Science for membership of a clinical trial academic steering committee. Dr Isaacs has no financial relationship with Eli Lilly. | 25/06/2024 15/01/2025 14/05/2025 | It was agreed that Dr Isaacs' declaration would not prevent him from providing expert advice to the committee. |
| Dr Jeremy Isaacs | Commissioning Expert | Direct – non-financial | Dr Isaacs has been a clinical triallist on commercial clinical trials of amyloid-lowering drugs in Alzheimer's disease sponsored by Roche. A clinical trial of donanemab in Alzheimer's disease sponsored by | 25/06/2024 15/01/2025 14/05/2025 | It was agreed that Dr Isaacs' declaration would not prevent him from providing expert advice to the committee. |

| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Comments |
|------------------|----------------------|-------------------------|---|------------------------------|--|
| | | | <p>Eli Lilly is currently in set up at Dr Isaac's institution (St George's University Hospitals NHS Foundation Trust) with him as the site principal investigator.</p> <p>Dr Isaacs has written an opinion piece in a journal about amyloid-lowering therapies, although this predated the publication of the pivotal phase 3 donanemab trial under consideration here: Alzheimer's disease: Have we opened the Golden Gate to disease-modifying therapy? - ScienceDirect</p> <p>Dr Isaacs is an author on a paper estimating potential demand for Alzheimer's DMTs in the UK: Estimating demand for potential disease-modifying therapies for Alzheimer's disease in the UK The British Journal of Psychiatry Cambridge Core</p> | | |
| Dr Jeremy Isaacs | Commissioning Expert | Indirect – professional | Dr Isaacs' partner is a Chair of one of the NICE TA appeal committees. | 25/06/2024 15/01/2025 | It was agreed that Dr Isaacs' declaration would not prevent him from |

| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Comments |
|-------------|-----------------------|-------------------------|--------------------------------|--------------------------|---|
| | | | | 14/05/2025 | providing expert advice to the committee. |

DRAFT